

Age-structured non-pharmaceutical interventions for optimal control of COVID-19 epidemic

Quentin Richard^a, Samuel Alizon^a, Marc Choisy^{a,b,c}
Mircea T. Sofonea^a, Ramsès Djidjou-Demasse^{a,*}

^aMIVEGEC, Univ. Montpellier, IRD, CNRS, Montpellier, France

^b Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford,
UK

^c Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

* Author for correspondence: ramses.djidjoudemasse@ird.fr

Abstract

In an epidemic, individuals can widely differ in the way they spread the infection, for instance depending on their age or on the number of days they have been infected for. The latter allows to take into account the variation of infectiousness as a function of time since infection. In the absence of pharmaceutical interventions such as a vaccine or treatment, non-pharmaceutical interventions (*e.g.* social distancing) are of great importance to mitigate the pandemic. We propose a model with a double continuous structure by host age and time since infection. By applying optimal control theory to our age-structured model, we identify a solution minimizing deaths and costs associated with the implementation of the control strategy itself. This strategy depends on the age heterogeneity between individuals and consists in a relatively high isolation intensity over the older populations during a hundred days, followed by a steady decrease in a way that depends on the cost associated to a such control. The isolation of the younger population is weaker and occurs only if the cost associated with the control is relatively low. We show that the optimal control strategy strongly outperforms other strategies such as uniform constant control over the whole populations or over its younger fraction. These results bring new facts the debate about age-based control interventions and open promising avenues of research, for instance of age-based contact tracing.

Key words. COVID-19; Optimal control; Age-structured model; Age of infection

1 Introduction

Following its emergence in December 2019, COVID-19 has become an international public health emergency [1]. The infection is similar to that caused by influenza virus regarding clinical presentation

30 and transmission mechanism [1]. Contrary to seasonal influenza, COVID-19 has become pandemic
31 by spreading rapidly among completely naive host populations, *i.e.* with no pre-existing immunity
32 [2–5]. At the start of the pandemic, no pharmaceutical interventions such as vaccines or treatments
33 were available and, based on earlier epidemics, it will take several months before their deployment.
34 For this reason, developing non-pharmaceutical intervention strategies, such as social distancing, is of
35 great importance to mitigate the pandemic [6].

36 Generally, age structure is a key determinant of such acute respiratory diseases, *e.g.* when it comes
37 to infection severity. For example, children are considered to be responsible for most of the transmis-
38 sion of influenza [7], but the related hospitalization and mortality burden is largely carried by people
39 of ages over 65 years [8, 9]. While much remains unknown about the COVID-19 epidemics, evidence
40 to date suggests that mortality among people who have been tested positive for the coronavirus is sub-
41 stantially higher at older ages and near zero for young children [3, 10]. Moreover, the infectiousness
42 of an individual has been reported to vary as a function of time since infection [11], which is known
43 to affect epidemic spread [12–14].

44 Here we propose an epidemiological model for the disease stage-progression [13] structured both
45 by the continuous age of the host population and the continuous age of infection. This formulation
46 differs from the existing literature where only one type of structure is considered at a time [15–18],
47 and is particularly suited to investigate an infection such as COVID-19, with strong host and infect age
48 effects. Indeed, in addition to taking into account the host population’s age structure, as well as the
49 gradient of disease severity from mild to critical symptoms, the model readily captures the variation
50 in infectiousness as a function of the time since infection. From a theoretical point of view, age-
51 structured models have been proposed to investigate the spread of acute respiratory diseases [19–23].
52 However, in a context of acute respiratory diseases with contact patterns, very few models consider
53 both structures as continuous variables, see for instance [18, 24].

54 In a context of non-pharmaceutical interventions, we adopt a modeling approach based on the
55 optimal control theory to determine the best strategy to implement during a finite time interval. In the
56 context of age-structured models, this approach allows one to determine the optimal strategies of age-
57 specific social distancing taking into consideration the cost of implementing such strategies [25–29].
58 Here, more specifically, we look for the intervention that significantly reduces morbidity associated
59 with COVID-19 at a minimal cost. In the same context, mathematical modeling using optimal control
60 theory has been carried out to identify optimal strategies involving non-pharmaceutical interventions
61 to control infectious diseases such as influenza and COVID-19 [30–33]. However, none of these
62 models take into account the age structure of the host population or the variation of the infectiousness
63 with the time since infection.

64 In Section 2, we first introduce the mathematical model. The model parameters and outputs are
65 then defined in Section 3. In Section 4, we characterize the optimal control strategy that minimizes the
66 number of deaths as well as the cost due to the implementation of the control strategy itself. Section 5
67 contains the main body of the results. We first analyse the epidemic spread without any intervention,

68 before comparing the performance of the optimal control in terms of deaths and hospitalizations for
 69 different costs of the control measure. Finally, the optimal control is compared to two other strategies
 70 using the same amount of resources to control the outbreak. The article ends by a Discussion in
 71 Section 6.

72 **2 The age-structured model of COVID-19**

73 **2.1 Model overview**

74 At time $t \in [0, T]$, the density of individuals of age $a \in [0, a_{max}]$ that are susceptible to the infection is
 75 denoted by $S(t, a)$. These individuals can become infected with a rate called the force of infection and
 76 denoted $\lambda(t, a)$. We assume that a fraction p of these individuals are paucisymptomatic, which means
 77 they will develop very mild to no symptoms, and enter group I_p . Note that this class can also be inter-
 78 preted as the fraction of the population that will not isolate themselves during their infection. Other
 79 individuals are assumed to develop more symptomatic infections, either severe I_s with proportion $q(a)$
 80 depending on the age a , or mild I_m with proportion $1 - q(a)$.

81 Each of the three infected host populations are structured in time since infection, so that $I_v(t, a, i)$,
 82 $v \in \{p, s, m\}$, denotes the density at time t of individuals of age a that have been infected for a duration
 83 $i \in \mathbb{R}_+$. Upon infection, all exposed individuals are assumed to remain non-infectious during an
 84 average period i_{lat} . Next, they enter an asymptomatic period during which they are infectious. Only
 85 I_m and I_s develop significant symptoms after an average time since infection i_{sympt} , which can allow
 86 them to self-isolate to limit transmission. During their infection, individuals can recover at a rate
 87 $h_v(a, i)$ ($v \in \{p, m, s\}$) that depends on the severity of the infection and the time since infection i .
 88 Severely infected individuals of age a may also die from the infection at rate $\gamma(a, i)$.

89 The infection life cycle is shown in Figure 1. The total size of the host population of age a at time
 90 t is

$$N(t, a) = S(t, a) + R(t, a) + \int_0^\infty (I_p(t, a, i) + I_m(t, a, i) + I_s(t, a, i)) di. \quad (1)$$

91 **2.2 Age-structured transmission and severity**

92 We use two components to model the infection process. First, we define the transmission probability
 93 $\beta_v(a, i)$ ($v \in \{p, m, s\}$) for each contact between an infected of age a and a susceptible person, which
 94 depends on the time since infection i . Second, we introduce the kernel $K(a, a')$ that represents the
 95 average number of contacts by unit of time between an individual of age a' and an individual of age
 96 a . Here, this contact matrix is informed by data from an earlier study conducted in France [34]. The
 97 force of infection underwent by susceptible individuals of age a at time t is then given by

$$\lambda(t, a, c) = (1 - c(t, a)) \int_0^{a_{max}} K(a, a') \int_0^\infty (\beta_s(a', i) I_s(t, a', i) + \beta_m(a', i) I_m(t, a', i) + \beta_p(a', i) I_p(t, a', i)) di da'. \quad (2)$$




Figure 1: **The model flow diagram.** Susceptible hosts of age a at time t ($S(t,a)$) are exposed to the virus with a force of infection $\lambda(t,a)$. A fraction p of exposed individuals, which are infected since time i , will never develop symptoms and enter the group of paucisymptomatic infections ($I_p(t,a,i)$). The rest will develop symptomatic infections, either severe ($I_s(t,a,i)$) with proportion $q(a)$ depending on age a of individuals, or mild ($I_m(t,a,i)$). Exposed individuals remain non-infectious for a duration i_{lat} after infection. Next, they become asymptomatic infectious and only symptomatic infected will develop symptoms at time i_{sympt} after infection. Infected individuals recover at rate $h_v(a,i)$. Only severely infected of age a die from the infection at rate $\gamma(a,i)$. Notations are shown in Table 1.

98 Here, $c(t,a)$ is the percentage of reduction of contacts towards people with age a , due to public
 99 measures, at time t . The total force of infection at time t in the whole population is computed as
 100 $\int_0^{a_{max}} \lambda(t,a,c)da$.

101 The dynamics of newly infected individuals (*i.e.* $i = 0$) in each group is thus defined by

$$\begin{cases} I_s(t,a,0) &= (1-p)q(a)\lambda(t,a,c)S(t,a), \\ I_m(t,a,0) &= (1-p)(1-q(a))\lambda(t,a,c)S(t,a), \\ I_p(t,a,0) &= p\lambda(t,a,c)S(t,a). \end{cases} \quad (3)$$

102 We assume that only severe infections I_s lead to hospitalization and we denote by

$$H(t) = \int_0^{a_{max}} \int_{i_{sympt}}^{\infty} I_s(t,a,i)di da \quad (4)$$

the total population hospitalized at time t , where i_{sympt} is the average time to symptoms onset. Each individual of age a dies at a rate $\mu(a,H(t))$ at time t , defined by

$$\mu(a,H(t)) = \mu_{nat}(a) + \mu_{add}(a,H(t)).$$

103 In the latter equation, μ_{nat} denotes the natural mortality rate when hospitals are not saturated. Further,
 104 we assume that this rate increases significantly as soon as the number of severe cases exceeds the
 105 healthcare capacity H_{sat} and μ_{add} is such additional death rate due to hospital saturation (see Section
 106 3.2).

We apply the same reasoning by assuming that the disease-related mortality can increase because of hospital saturation. Therefore, severely infected individuals of age a infected since time i die at time t at rate $\gamma(a,i,H(t))$ defined by

$$\gamma(a,i,H(t)) = (\gamma_{dir}(a) + \gamma_{indir}(a,H(t))) \mathbf{1}_{[i_{sympt}, i_{max}]}(i).$$

107 Here, γ_{dir} and γ_{indir} are mortality rates directly and indirectly due to the COVID-19 respectively (see
 108 Section 3.2). The disease-related mortality occurs after the emergence of symptoms and before the
 109 mean final time of infection for severe cases, *i.e.* for $i \in [i_{sympt}, i_{max}^s]$.

110 Finally, infected individuals of age a infected since time i recover at rates $h_s(a, i)$, $h_m(a, i)$ and
 111 $h_p(a, i)$ for severe, mild and paucisymptomatic infections respectively.

112 The boundary conditions (3) are coupled with the following equations:

$$\left\{ \begin{array}{l} \frac{\partial S}{\partial t}(t, a) = -\mu(a, H(t))S(t, a) - \lambda(t, a, c)S(t, a), \\ \left(\frac{\partial I_s}{\partial t} + \frac{\partial I_s}{\partial i}\right)(t, a, i) = -[\mu(a, H(t)) + \gamma(a, i, H(t)) + h_s(a, i)]I_s(t, a, i), \\ \left(\frac{\partial I_m}{\partial t} + \frac{\partial I_m}{\partial i}\right)(t, a, i) = -[\mu(a, H(t)) + h_m(a, i)]I_m(t, a, i), \\ \left(\frac{\partial I_p}{\partial t} + \frac{\partial I_p}{\partial i}\right)(t, a, i) = -[\mu(a, H(t)) + h_p(a, i)]I_p(t, a, i), \\ \frac{\partial R}{\partial t}(t, a) = \sum_{v \in \{s, m, p\}} \int_0^\infty h_v(a, i)I_v(t, a, i)di - \mu(a, H(t))R(t, a), \end{array} \right. \quad (5)$$

for any $(t, a, i) \in (0, T] \times [0, a_{max}] \times \mathbb{R}_+$, with initial conditions (at $t = 0$):

$$S(0, a) = S_0(a), \quad R(0, a) = 0, \quad I_s(0, a, i) = I_{s,0}(a, i), \quad I_m(0, a, i) = I_{m,0}(a, i), \quad I_p(0, a, i) = I_{A,0}(a, i)$$

for each $(a, i) \in [0, a_{max}] \times \mathbb{R}_+$. The initial conditions of infected populations are detailed in Section 3.3. Using (3) and an integration over i of (5), one may observe that the total population N defined by (1) is strictly decreasing since it satisfies the following inequality:

$$\frac{\partial N}{\partial t}(t, a) \leq -\mu_{nat}(a)N(t, a), \quad \forall a \in [0, a_{max}], \quad \forall t \geq 0.$$

113 This is due to the fact that population aging and births are neglected in this model since we consider a
 114 time horizon of only one year. Further, basic properties of the model such as existence and positiveness
 115 of solutions is out of the primary scoop of our study. However, these can be specifically addressed
 116 using an integrated semigroup approach and Volterra integral formulation (see [35–38] and references
 117 therein).

118 3 Epidemiological outputs, model parameters and initial conditions

119 In this section we briefly describe some useful epidemiological outputs, the shape of age dependent
 120 parameters considered for the simulations of model (3)-(5), and the initial conditions. All state vari-
 121 ables and other parameters are summarized in Table 1.

122 3.1 Epidemiological outputs

123 In addition to the total number of hospitalized cases $H(t)$ at time t defined by (4), we define additional
 124 epidemiological outputs such as the number of non-hospitalized cases ($N_H(t)$), the cumulative number

125 of deaths due to COVID-19 directly ($D_{dir}^{cum}(t)$) and indirectly ($D_{indir}^{cum}(t)$) respectively by

$$N_H(t) = \int_0^{a_{max}} \left[\int_0^{i_{symp}} I_s(t, a, i) di + \int_0^{\infty} (I_m(t, a, i) + I_p(t, a, i)) di \right] da, \quad (6)$$

126 and

$$D_{dir}^{cum}(t) = \int_0^t D_{dir}(s) ds, \quad D_{indir}^{cum}(t) = \int_0^t D_{indir}(s) ds, \quad (7)$$

127 where $D_{dir}(t)$ and $D_{indir}(t)$ are the number of deaths at time t respectively defined by

$$D_{dir}(t) = \int_0^{a_{max}} \int_{i_{symp}}^{i_{max}^s} \gamma_{dir}(a) I_s(t, a, i) di da,$$

$$D_{indir}(t) = \int_0^{a_{max}} \mu_{add}(a, H(t)) N(t, a) da + \int_0^{a_{max}} \gamma_{indir}(a, H(t)) \int_{i_{symp}}^{i_{max}^s} I_s(t, a, i) di da.$$

Note that non-hospitalized cases N_H defined by (6) are composed of the paucisymptomatic, the mildly infected, and the severely infected but not yet hospitalized populations. We can also note that every output aforementioned implicitly depends on parameter c which we will omit when no confusion is possible. However, in order to compare different public health measures we will explicitly write this dependence. The relative performance between two strategies c_1 and c_2 , denoted by $\Delta(c_1, c_2)$, is estimated by assessing the cumulative number of deaths in the whole population during the T days of control period with the strategy c_1 relatively to deaths with the strategy c_2 . Formally we have

$$\Delta(c_1, c_2) = 1 - \frac{D_{dir}^{cum}(c_1, T) + D_{indir}^{cum}(c_1, T)}{D_{dir}^{cum}(c_2, T) + D_{indir}^{cum}(c_2, T)}.$$

128 Hence, a relative performance $\Delta(c_1, c_2) = 0.1$ implies that the strategy c_1 reduces the number of deaths
129 by 10% relatively to c_2 .

130 3.2 Setting model parameters

131 We assume mortality rates indirectly due to the COVID-19 to grow as the number of hospitalisations
132 H exceeds a healthcare capacity threshold H_{sat} . The natural mortality rate increases by $\mu_{add}(a, H)$ in
133 the whole population and by $\gamma_{indir}(a, H)$ for severely infected individuals of age a . These rates are
134 respectively defined by logistic functions that are arbitrarily chosen as:

$$\mu_{add}(a, H(t)) = \frac{10^{-2} \mu_{nat}(a)}{1 + 99 \exp\left(-10 \left(\frac{H(t)}{H_{sat}} - 1\right)\right)}, \quad \gamma_{indir}(a, H(t)) = \frac{\gamma_{dir}(a)}{1 + 99 \exp\left(-10 \left(\frac{H(t)}{H_{sat}} - 1\right)\right)}. \quad (8)$$

This choice of functional parameters implies that

$$\mu_{add}(a, 0) \approx 0, \quad \gamma_{indir}(a, 0) \approx 0, \quad \mu_{add}(a, H_{sat}) = 10^{-2} \mu_{nat}(a), \quad \gamma_{indir}(a, H_{sat}) = 10^{-2} \gamma_{dir}(a)$$

so that those additional mortalities are negligible when hospitals are not saturated (Figure 2 b,c). In case of saturation, the following estimates hold:

$$\lim_{H \rightarrow \infty} \mu_{add}(a, H) = 10^{-2} \mu_{nat}(a), \quad \lim_{H \rightarrow \infty} \gamma_{indir}(a, H) = \gamma_{dir}(a)$$




Figure 2: (a) Transmission probabilities of paucisymptomatic infections β_p , symptomatic severe β_s and mild infections β_m . (b)-(c) Mortality rates due to the healthcare system saturation, with a maximal healthcare capacity $H_{sat} = 5 \times 10^3$.

135 for each $a \in [0, a_{max}]$, meaning that the natural mortality rate is only increased by 1%, while the
 136 disease-induced mortality rate γ is doubled. Indeed, according to [39], 50% of patients in critical care
 137 will die in case of no saturation of hospitals. Here, we then make the assumption that this percentage
 138 will grow to 100% in case of over-saturation of hospitals.

139 The infectiousness of an individual aged a , which is infected since time i , is given by $\beta_v(a, i)$
 140 ($v \in \{s, m, p\}$). Based on estimates described in [11], we assume that β_v does not depends on age a ,
 141 *i.e.*, $\beta_v(a, i) = \beta_v(i)$. This assumption is only for parameterization purpose and does not impact the
 142 general formulation of the model proposed here (this is discussed later in Section 6). Next, we set
 143 $\beta_v(i) = \alpha \times \xi_v(i) \times \bar{\beta}(i)$, for $v \in \{s, m, p\}$. Here, as explained below, α is a scaling parameter obtained
 144 from the value of the basic reproduction number R_0 . Parameter $\bar{\beta}$ is assumed to be identical to that
 145 reported in [11] and to follow a Weibull distribution $\bar{\beta} \sim W(3, 5.65)$. Parameters $\xi_v(i)$ are factors
 146 capturing the reduction of the transmission probability. For paucisymptomatic individuals, these are
 147 assumed to be constant ($\xi_p(i) = \xi_p$), while the reduction factor in more symptomatic infections (severe
 148 and mild) is assume to vary after symptom onset to capture admission in a healthcare facility or self-
 149 isolation at home. More precisely, we assume that

$$\xi_s(i) = \begin{cases} 1 & \text{if } i \in [0, i_{sympt}], \\ e^{-\ln(10)(i-i_{sympt})} & \text{if } i > i_{sympt} \end{cases}, \quad \text{and } \xi_m(i) = \begin{cases} 1 & \text{if } i \in [0, i_{sympt}], \\ e^{-\ln(2)(i-i_{sympt})} & \text{if } i > i_{sympt}. \end{cases} \quad (9)$$

150 These two functions are chosen arbitrarily by assuming that individuals do not isolate before symp-
 151 toms onset ($i \leq i_{sympt}$), and that isolation is stronger when symptoms are more severe (Figure 2 (a)).
 152 We therefore assume that the transmission probability $\bar{\beta}$ is divided by 10 (respectively 2) every day
 153 after the average time of symptoms onset for individuals severely (resp. mildly) infected.

154 Finally, we assume that recover rates $h_v(a, i)$, $v \in \{s, m, p\}$, of infected individuals of age a infected
 155 since time i are independent of the age a and take the following form:

$$h_s(\cdot, i) = \mathbf{1}_{[i_{max}, \infty]}(i), \quad h_m(\cdot, i) = h_p(\cdot, i) = \mathbf{1}_{[i_{max}, \infty]}(i), \quad \forall i \in \mathbb{R}_+. \quad (10)$$

156 That is, one can recover from severe (resp. mild and paucisymptomatic) infections only after a time
 157 since infection i_{\max}^s (resp. i_{\max}^m) corresponding to the mean duration of infection.

158 3.3 Initial conditions

According to the French public health agency [44], there were 130 confirmed cases of COVID-19 in France on March 1st, 2020, which we will consider as $t = 0$ in our model. Since tests in France were initially performed based on severe symptoms, we assume that all those cases are severe infections. Thus, we set $\int_{i_{\text{sympt}}}^{i_{\max}^s} \int_0^{a_{\max}} I_{s,0}(a, i) da di = 130$ as the initial severely infected individuals, which is assumed to be uniformly distributed with respect to the time since infection i on the interval $[0, i_{\max}^s]$. Using estimates from [44, 45] on the age distribution of hospitalised people, we derive an estimation of $I_{s,0}(a, i)$ for each $(a, i) \in [0, a_{\max}] \times \mathbb{R}_+$. Next, following the life cycle (Figure 1), we obtain an estimation of the total initial infected population by $\frac{I_{s,0}(a, i)}{(1-p)q(a)}$. From there, we deduce the initial mildly and paucisymptomatic infected populations respectively by

$$I_{m,0}(a, i) = \frac{1-q(a)}{q(a)} I_{s,0}(a, i) \quad \text{and} \quad I_{A,0}(a, i) = \frac{p}{q(a)(1-p)} I_{s,0}(a, i).$$

159 The initial susceptible population size S_0 comes from the French National Institute of Statistics and
 160 Economic Studies [42].

161 4 Optimal intervention

In this section, following well established methodology in optimal control theory [25–28, 46], we search for the optimal control effort function c^* that minimizes the objective functional $J : L^\infty(\mathbb{R}_+ \times [0, a_{\max}]) \ni c \mapsto J(c) \in \mathbb{R}$, where

$$J(c) = D_{dir}^{cum}(c, T) + D_{indir}^{cum}(c, T) + \int_0^T \int_0^{a_{\max}} B(a) c^2(t, a) da dt,$$

162 where $D_{dir}^{cum}, D_{indir}^{cum}$ are cumulative number of deaths defined by (7) and $B(a)$ is the cost associated with
 163 the implementation of such control c for the age class a . Our aim is to find the function c^* satisfying

$$J(c^*) = \min_{c \in \mathcal{U}} J(c) \tag{11}$$

wherein the set \mathcal{U} is defined by

$$\mathcal{U} = \{c \in L^\infty(\mathbb{R}_+ \times [0, a_{\max}]) : 0 \leq c(\cdot, \cdot) \leq c_{\max}\},$$

164 with $c_{\max} \leq 1$ a positive constant. That is to say, the function c^* will minimize the cumulative number
 165 of deaths during T days, as long as the cost of the control strategy is not too large.

State variables		
S	Susceptible individuals	
I_s	Severely infected individuals	
I_m	Mildly infected individuals	
I_p	Paucisymptomatic infected individuals	
R	Recovered individuals	
Model parameters		
Param.	Description (unit)	Values [source]
t, T	time and final time of simulations (days)	$t \in [0, T]$ (ad hoc)
a, a_{\max}	age and maximal age of individuals (years)	$a \in [0, a_{\max}]$, $a_{\max} = 100$ (ad hoc)
i	time since infection (days)	\mathbb{R}_+ (ad hoc)
i_{lat}	latency from exposed to asympt. (days)	4.2 [40]
i_{sympt}	average time of symptoms onset (days)	$i_{lat} + 1 = 5.2$ [39]
i_{\max}^s	mean final time of infection for severe cases (days)	$i_{sympt} + 20 = 25.2$ [41]
i_{\max}^m	mean final time of infection for mild cases (days)	$i_{sympt} + 17 = 22.2$ [41]
S_0	initial population of susceptible	[42]
μ_{nat}	natural death rate (days^{-1})	[43]
μ_{add}	additional death rate (days^{-1})	defined by (8)
H_{sat}	maximal healthcare capacity	5×10^3 [44]
$\beta_s, \beta_m, \beta_p$	transmission probabilities (unitless)	computed in Section 3.2
ξ_s, ξ_m, ξ_p	infectiousness reduction factors (unitless)	defined by (9) and $\xi_p = 0.1$ [11]
h_s, h_m, h_p	recovery rates per infection (days^{-1})	defined by (10)
K	matrix of social contacts (days^{-1})	[34]
c, c_{\max}	public health measure and its upper bound (unitless)	$c \in [0, c_{\max}]$, $c_{\max} = 0.95$ (assumed)
γ_{dir}	mortality rate directly due to the COVID-19 (days^{-1})	[39]
γ_{indir}	mortality rate indirectly due to the COVID-19 (days^{-1})	defined by (8)
p	proportion of paucisymptomatic (unitless)	variable
q	proportion of symptomatic requiring hospitalisation (unitless)	[39]
B	cost of the control measure (unitless)	variable

Table 1: Model variables and parameters

166 Let (S, I_s, I_m, I_p, R) be a given solution of (3)-(5) then let λ and H be respectively defined by (2)
 167 and (4). After some computations (Appendix B), we find that the adjoint system of (5) reads as

$$\begin{pmatrix} \frac{\partial z_S}{\partial t}(t, a) \\ \frac{\partial z_R}{\partial t}(t, a) \\ \left(\frac{\partial z_{I_s}}{\partial t} + \frac{\partial z_{I_s}}{\partial i}\right)(t, a, i) \\ \left(\frac{\partial z_{I_m}}{\partial t} + \frac{\partial z_{I_m}}{\partial i}\right)(t, a, i) \\ \left(\frac{\partial z_{I_p}}{\partial t} + \frac{\partial z_{I_p}}{\partial i}\right)(t, a, i) \end{pmatrix} = \begin{pmatrix} \mu(a, H(t))z_S(t, a) - \mu_{add}(a, H(t)) \\ \mu(a, H(t))z_R(t, a) - \mu_{add}(a, H(t)) \\ (\mu(a, H(t)) + h_s(a, i))z_{I_s}(t, a, i) - \mu_{add}(a, H(t)) - \gamma(a, i, H(t))(1 - z_{I_s}(t, a, i)) \\ (\mu(a, H(t)) + h_m(a, i))z_{I_m}(t, a, i) - \mu_{add}(a, H(t)) \\ (\mu(a, H(t)) + h_p(a, i))z_{I_p}(t, a, i) - \mu_{add}(a, H(t)) \end{pmatrix} \\ - \begin{pmatrix} \zeta_2(t, a) \int_0^\infty \int_0^{a_{\max}} K(a, a')(\beta_s(a', i)I_s(t, a', i) + \beta_m(a', i)I_m(t, a', i) + \beta_p(a', i)I_p(t, a', i)) da' di \\ 0 \\ \zeta_1(t, a) \mathbf{1}_{[i_{\text{sympt}}, \infty)}(i) + \beta_s(a, i) \int_0^{a_{\max}} \zeta_2(t, a') S(t, a') K(a', a) da' + \zeta_3(t, a) h_s(a, i) \\ \beta_m(a, i) \int_0^{a_{\max}} \zeta_2(t, a') S(t, a') K(a', a) da' + \zeta_3(t, a) h_m(a, i) \\ \beta_p(a, i) \int_0^{a_{\max}} \zeta_2(t, a') S(t, a') K(a', a) da' + \zeta_3(t, a) h_p(a, i) \end{pmatrix} \quad (12)$$

with final conditions $z_S(T, a) = z_R(T, a) = 0$, $z_u(T, a, i) = 0$ and $\lim_{i \rightarrow \infty} z_u(t, a, i) = 0$, for any $u \in \{I_s, I_m, I_p\}$ and $(a, i) \in [0, a_{\max}] \times \mathbb{R}_+$, while ζ_k ($k \in \{1, 2, 3\}$) satisfy the system:

$$\begin{pmatrix} \zeta_1(t, a) \\ \zeta_2(t, a) \\ \zeta_3(t, a) \end{pmatrix} = \begin{pmatrix} \frac{\partial \mu}{\partial H}(a, H(t))(S(t, a)(1 - z_S(t, a)) + R(t, a)(1 - z_R(t, a))) \\ [1 - c(t, a)][(1 - p)(q(a)z_{I_s} + (1 - q(a))z_{I_m}) + pz_{I_p}](t, a, 0) - (1 - c(t, a))z_S(t, a) \\ z_R(t, a) \end{pmatrix} \\ + \begin{pmatrix} \int_0^\infty \frac{\partial \mu}{\partial H}(a, H(t))(I_s(t, a, i)(1 - z_{I_s}(t, a, i)) + I_m(t, a, i)(1 - z_{I_m}(t, a, i))) di \\ 0 \\ 0 \end{pmatrix} \\ + \begin{pmatrix} \int_0^\infty \left(\frac{\partial \mu}{\partial H}(a, H(t))I_p(t, a, i)(1 - z_{I_p}(t, a, i)) + \frac{\partial \gamma}{\partial H}(a, i, H(t))I_s(t, a, i)(1 - z_{I_s}(t, a, i)) \right) di \\ 0 \\ 0 \end{pmatrix}. \quad (13)$$

168 Finally, the Hamiltonian \mathcal{H} of (11) is given by (B.1). Then, solving $\frac{\partial \mathcal{H}}{\partial c} = 0$, it comes that

$$c^*(t, a) = \max(0, \min(\hat{c}(t, a), 1)), \quad (14)$$

for every $(t, a) \in [0, T] \times [0, a_{\max}]$, where

$$\hat{c}(t, a) = \frac{S(t, a)\lambda_0(t, a) [(1 - p)(1 - q(a))z_{I_m}(t, a, 0) + (1 - p)q(a)z_{I_s}(t, a, 0) + pz_{I_p}(t, a, 0)]}{2B(a)},$$

169 with λ_0 defined by (A.4).

We also assume that the cost $B(a)$ of the control measure over individuals aged $a \in [0, a_{\max}]$ is proportional to their density in the initial susceptible population S_0 , *i.e.*

$$B(a) = \frac{B^* S_0(a)}{\int_0^{a_{\max}} S_0(u) du},$$

170 where $B^* \in \mathbb{R}_+$ is a variable parameter characterizing the relative cost in implementing the strategy.
171 Additionally, one may consider the age distribution of the economic cost on the shape of the function
172 B . For example, the economic cost can be assumed more important for the working population (*i.e.*
173 age group 20 – 60) compared to the older. Though, in absence of relevant references on this topic we
174 stand with our primary assumption.

175 The state system (3)-(5) and the adjoint system (12)-(13) together with the control characteriza-
176 tion (14) form the optimality system to be solved numerically. Since the state equations have initial
177 conditions and the adjoint equations have final time conditions, we cannot solve the optimality system
178 directly by only sweeping forward in time. Thus, an iterative algorithm, forward-backward sweep
179 method, is used [47]. In other words, finding c^* numerically, involves first solving the state vari-
180 ables (3)-(5) forward in time, then solving the adjoint variables (12)-(13) backward in time, and then
181 plugging the solutions for the relevant state and adjoint variables into (14), subject to bounds on the
182 control function. Finally, the proof of the existence of such control is standard and is mostly based
183 on the Ekeland’s variational principle [48]. Therefore, existence of the optimal control to the above
184 problem is assumed and we refer to [25] for more details.

185 5 Results

186 5.1 The basic reproduction number R_0

An explicit expression of the R_0 of model (3)-(5) is difficult to obtain in general. We show in Ap-
pendix A that it is possible to write $R_0 = \alpha \times r(U)$, where α is the scaling parameter introduced in
Section 3.2, and $r(U)$ is the spectral radius of the next generation operator U defined on $L^1(0, a_{\max})$
by

$$U : L^1(0, a_{\max}) \ni v \mapsto S_0(\cdot) \int_0^\infty \int_0^{a_{\max}} K(\cdot, a') \omega(a', i) v(a') da' di \in L^1(0, a_{\max}).$$

where S_0 is the initial susceptible population, K is the contact matrix and $\omega(a, i)$ is the infectiousness
of individuals of age a infected since time i (Appendix A). We set $R_0 = 3.3$ [49, 50] and it follows that

$$\alpha = \frac{R_0}{r(\bar{U})}.$$

187 Using a numerical approach, we find $r(\bar{U}) \approx 12.074$, whence $\alpha \approx 0.575$.

188 5.2 Typical outbreak dynamics simulated with the model

189 Numerical simulations are based on the reference values of the model parameters defined previously
190 and summarized in Table 1, with $R_0 = 3.3$.

191 We first use the model to describe the outbreak of the epidemics without any public health measure
192 (*i.e.* $c \equiv 0$). The peak of the epidemics is reached approximately at day $t = 54$ for hospitalised people,
193 and day $t = 48$ for non-hospitalised (Figure 3a). The delay between the two peaks is due to the
194 latency time i_{sympt} for symptoms onset (Table 1). The healthcare capacity is quickly exceeded (about
195 twenty days) and the number of deaths increases sharply from then on. At the end of the simulation
196 ($t = 150$ days), the total number of infections (severe, mild and paucisymptomatic) is around 90.1%
197 and varies with the age class considered (Figure 3b). Further, in each age class the proportion of
198 infected individuals is larger than the theoretical herd immunity threshold given by $1 - 1/R_0 \approx 69.7\%$
199 (Figure 3b). While people older than 70 are the less affected (in proportion), they however represent
200 the age class with the highest cumulative number of deaths (Figure 3c). On the contrary, most of the
201 infections that occur in the young population do not require hospitalisation (Figure 3d,e).

202 **5.3 Effect of the optimal intervention**

203 In this section, we investigate the interaction between the optimal intervention and the age structure
204 of the population. We illustrate the optimal intervention strategy and their performance in terms of
205 cumulative number of deaths for three costs of the control (relatively low $B^* = 10^2$, intermediate
206 $B^* = 10^3$ and high $B^* = 10^4$). Overall, the optimal control particularly targets the older populations
207 compared to the younger ones (Figure 4). If the cost B^* is relatively high, the optimal control is
208 almost restricted to individuals above 55, with a significant reduction in deaths (Figure 4d,e). This
209 strict lock down of older individuals lasts approximately 100 days for $B^* = 10^3$ and 10^4 . The relative
210 performance of the optimal control c^* compared to a doing nothing scenario ($\Delta(c^*, 0)$) is at least 92%
211 (resp. 82%) when the cost is $B^* = 10^3$ (resp. 10^4). With a low cost of the control measure ($B^* = 10^2$),
212 the optimal control significantly extends to younger populations (Figure 4a), with a maximum reached
213 near the 4th month of the epidemics and a steady decrease until the end of the control period. At first,
214 the control is over people above 35 but that after 2 or 3 months the control begin to extend to people
215 less than 35. The resulting reduction in the number of deaths is very pronounced with a relative
216 performance $\Delta(c^*, 0)$ of at least 99%.

217 **5.4 Comparative analysis and practicability of the optimal control**

218 We investigated how the optimal strategy compares to other control strategies that use the same amount
219 of ‘resources’ (that is the same cumulative cost). Assuming an relatively high cost $B^* = 10^3$, we inves-
220 tigated a uniform control strategy (denoted by c^u) either over the younger fraction of the population
221 (Figure 5a) or over the whole population with level $c_{\text{max}} = 0.95$ (Figure 5b). The effect of these strat-
222 egy lasts about 55 days during which the epidemic is suppressed. However, once the control resources
223 are exhausted, the epidemic reemerges (Figure 5c) and, in the end, the cumulative mortality over the
224 time period of interest is comparable to that without any control measure (Figure 5d) and relative
225 performance $\Delta(c^*, c^u)$, of the optimal control c^* relatively to the uniform control c^u , is approximately




Figure 3: Epidemic simulated with default parameter values and no intervention with $p = 0.5$. (a) Dynamics of epidemiological outputs over time: number of hospitalised, non hospitalised, cumulative deaths, recovered and susceptible. (b) Age distribution of the proportion of the population that have been infected before 150 days. (c) The number of cumulative deaths by age class and over time. (d)-(e) Density of hospitalised and non-hospitalised people by age class over time.

226 92%. With the (longer) uniform control over the younger fraction of the population, the first epidemic
 227 peak is slightly delayed, but a second peak appears a few months later (Figure 5c). With this strategy,
 228 the cumulative mortality comparable to the one without any control measure (Figure 5d).

229 The optimal control is a continuous function and is then quite difficult to enforce in practice.
 230 However, we can derive step functions leading to practical implementations of the optimal control.
 231 For instance, the population is subdivided into 10-year amplitude classes and the control is updated
 232 every 3-weeks by keeping a constant amount of control during each 3-weeks period for each age-class.
 233 (Figure S1). Importantly, the constant defining the control intensity for each period is captured from
 234 the knowledge of the continuous optimal control strategy. The effect of such strategy is overall similar
 235 to the optimal control (Figure S1) with a relative performance of 91% compared to a doing nothing
 236 scenario.




Figure 4: The optimal control strategy c^* plotted over time, age and its intensity, as well as their performance in terms of cumulative number of deaths for three costs of the control measure. (a) relatively low $B^* = 10^2$, (b) intermediate $B^* = 10^3$, (c) high $B^* = 10^4$. (d) Number of hospitalizations. (e) Cumulative deaths per age at final time $T = 365$ days. The relative performance $\Delta(c^*, 0)$ of the optimal control c^* compared to a doing nothing scenario is at least 99% (resp. 92%, 82%) with $B^* = 10^2$ (resp. 10^3 , 10^4). Here $p = 0.5$.




Figure 5: **Comparing optimal control with uniform control.** (a) Illustration of the uniform control over the young population and (b) independently of the age. (c) Number of hospitalizations. (d) Cumulative deaths per age at final time $T = 365$ days. Here, we assume $B^* = 10^3$. Here $p = 0.5$.

237 6 Discussion

238 Non-pharmaceutical public health interventions can be implemented either to mitigate the COVID-19
239 epidemic wave, and rely on natural immunisation, or to suppress the wave long enough to develop and
240 implement a vaccine or a treatment. Here, we explicitly factor in the age heterogeneity of the host
241 population in the identification of the optimal allocation of the control efforts.

242 We use optimal control theory to characterize an optimal strategy that significantly reduces the
243 number of deaths, while being sustainable at the population level. Our formulation assume a quadratic
244 cost for the control effort. We find that, with this strategy, the intensity of the control is always
245 relatively high on the older fraction of the population during at least a hundred days, before decreasing
246 more or less rapidly depending on the cost associated to the control. The control over the younger
247 fraction of the population is weak and only occurs when the cost associated with the optimal control
248 is relatively low and, even then, the level control only increases 2 or 3 months after that on the older
249 fraction of the population. This late control over the younger part of the population actually mimics
250 the results [31] where the control didn't peak right away. Intuitively, if control strategies come at a
251 high cost for the population, it is best to focus on the age classes that are the most at risk. Conversely,
252 if the control measures are more acceptable to the population, the optimal strategy is to aim wide in
253 order to completely suppress the epidemic wave.

254 Information on the natural history of paucisymptomatic infections of COVID-19 remains rela-
255 tively little-known [51, 52]. It is estimated that a proportion p of infected individuals will remain
256 asymptomatic throughout the course of infection. However, this proportion remains largely unspeci-
257 fied in the literature [51, 52]. We explored effects of the proportion p on the optimal control strategy
258 c^* . Overall, the proportion of paucisymptomatic infections have marginal effect of the optimal control
259 strategy (Figure S2). The optimal control remains strong over the older population from the beginning
260 of the epidemic, before progressively alleviated. The control over the younger population is weaker
261 and occurs only if control cost itself is low. But, the level of control over its younger fraction in-
262 creases when the proportion of paucisymptomatic infections decreases. Further, for high values of
263 $B^* \in \{10^3, 10^4\}$, the shape of the optimal control does not change with the proportion p (Figure S2).
264 Indeed, the epidemics cannot be stopped and the strategy is then to reduce mortality by protecting the
265 population the most at risk (here the older population). However, with low value of $B^* = 10^2$, different
266 shape of the optimal control give the same result since there is enough resources to stop the epidemics.

267 Given the leverage represented by school and university closure, we investigated the effect of
268 control measures over individuals aged under 25. Our results show that NPIs targeting the younger
269 fraction of the population are not very efficient in reducing cumulative mortality, unless they can be
270 implemented strongly and for a relatively long period. Indeed, a control only over the younger popu-
271 lation barely reduces the number of deaths by 3% compared to a doing nothing scenario (Figure 5a,c).
272 Note that this result could depend on the contact matrix between ages, for which there is little date in
273 France (here we used the one found by [34]). Furthermore, transmission probability could vary with

274 age, as discussed below.

The model proposed here is an extension of the classical models based on ordinary differential equations that tackled the issue of the optimal control of COVID-19 outbreak [30–33]. Here, the whole population is structured by age (a) and additionally by the time since infection (i) for infectious individuals, which echoes the model developed in [50] using a discrete-time formulation of the infection. With our continuous structure, we show that the number of new cases $I_N(t, a)$ at time t in individuals of age a is given by the renewal equation

$$I_N(t, a) = S_0(a) \int_0^\infty \int_0^{a_{\max}} K(a, a') \omega(a', i) I_N(t - i, a') da' di,$$

275 where K is the contact matrix and $\omega(a, i)$ is the infectiousness of individuals aged a which are infected
276 since time i (Appendix A). For parameterisation purposes, we assume that $\omega(a, i)$ is the product
277 between the proportion of individuals of age a in the whole population and the infectiousness $\bar{\beta}(i)$ of
278 individuals infected since time i . This is potentially a strong limitation since infectiousness $\bar{\beta}$ could
279 depend on the age a thereby creating an additional heterogeneity in addition to that since the time
280 since infection i . This issue can be particularly important since some studies suggest a low risk of
281 transmission in the young population (e.g. [53]).

282 Another potential limitation is the lack of gender structure in the model formulation. Given the
283 observed male biased in mortality during the COVID-19 pandemic, it has been suggested that males
284 are more at risk of developing severe infections [54]. This heterogeneity could readily be introduced
285 in the model.

286 Contacts networks have an important role in transmission dynamic models. Epidemic models
287 that determine which interventions can successfully prevent an outbreak may benefit from account-
288 ing for social structure and mixing patterns. Contacts are highly assortative with age across a given
289 country, but regional differences in the age-specific contacts is noticeable [55]. The current model
290 could be modified to explore epidemiological dynamics in a spatially structured population with non-
291 homogeneous mixing, e.g. by using a meta-population model [56].

292 Another potential extension of the model would be to allow for the isolation of symptomatic cases
293 and their contacts, following the method developed in [57] and applied recently to digital contact
294 tracing [11]. Indeed, these measures strongly depend on the relative timing of infectiousness and
295 the appearance of symptoms, and the formulation of the presented model seems suitable for that.
296 However, this also raises technical challenges due to the double continuous structure. However, being
297 able to identify age classes to follow in priority with contact tracing could be an asset in controlling
298 epidemic spread.

299 References

- 300 [1] Coronavirus Disease (COVID-19) Situation Reports;. [https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
301 [coronavirus-2019/situation-reports](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports).

- 302 [2] Dorigatti I, Okell L, Cori A, Imai N, Baguelin M, Bhatia S, et al. Report 4: Severity of 2019-
303 Novel Coronavirus (nCoV). 2020;p. 12.
- 304 [3] Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the Severity
305 of Coronavirus Disease 2019: A Model-Based Analysis. *The Lancet Infectious Diseases*. 2020
306 Mar;0(0).
- 307 [4] Famulare M. 2019-nCoV: Preliminary Estimates of the Confirmed-Case-
308 Fatality-Ratio and Infection-Fatality-Ratio, and Initial Pandemic Risk
309 Assessment; 2020. [https://instituteofdiseasemodeling.github.io/nCoV-](https://instituteofdiseasemodeling.github.io/nCoV-public/analyses/first_adjusted_mortality_estimates_and_risk_assessment/2019-nCoV-preliminary_age_and_time_adjusted_mortality_rates_and_pandemic_risk_assessment.html)
310 [public/analyses/first_adjusted_mortality_estimates_and_risk_assessment/2019-nCoV-](https://instituteofdiseasemodeling.github.io/nCoV-public/analyses/first_adjusted_mortality_estimates_and_risk_assessment/2019-nCoV-preliminary_age_and_time_adjusted_mortality_rates_and_pandemic_risk_assessment.html)
311 [preliminary_age_and_time_adjusted_mortality_rates_and_pandemic_risk_assessment.html](https://instituteofdiseasemodeling.github.io/nCoV-public/analyses/first_adjusted_mortality_estimates_and_risk_assessment/2019-nCoV-preliminary_age_and_time_adjusted_mortality_rates_and_pandemic_risk_assessment.html).
- 312 [5] Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating Clinical
313 Severity of COVID-19 from the Transmission Dynamics in Wuhan, China. *Nature Medicine*.
314 2020 Mar;p. 1–5.
- 315 [6] Adam D. Special Report: The Simulations Driving the World’s Response to COVID-19. *Nature*.
316 2020 Apr;580(7803):316–318.
- 317 [7] Brownstein JS, Kleinman KP, Mandl KD. Identifying Pediatric Age Groups for Influenza Vac-
318 cination Using a Real-Time Regional Surveillance System. *American Journal of Epidemiology*.
319 2005 Oct;162(7):686–693.
- 320 [8] McBean AM, Hebert PL. New Estimates of Influenza-Related Pneumonia and Influenza Hospi-
321 talizations among the Elderly. *International journal of infectious diseases: IJID: official publica-*
322 *tion of the International Society for Infectious Diseases*. 2004 Jul;8(4):227–235.
- 323 [9] Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-
324 Associated Hospitalizations in the United States. *JAMA*. 2004 Sep;292(11):1333–1340.
- 325 [10] Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in
326 Relation to COVID-19 in Italy. *JAMA*. 2020 Mar;.
- 327 [11] Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dörner L, et al. Quantifying SARS-
328 CoV-2 Transmission Suggests Epidemic Control with Digital Contact Tracing. *Science*. 2020
329 Mar;.
- 330 [12] Kermack WO, McKendrick AG. A Contribution to the Mathematical Theory of Epidemics. *Proc*
331 *R Soc Lond A*. 1927;115:700–721.
- 332 [13] Anderson RM, May RM. *Infectious Diseases of Humans. Dynamics and Control*. Oxford:
333 Oxford University Press; 1991.

- 334 [14] Hethcote HW. The Mathematics of Infectious Diseases. SIAM review. 2000;42(4):599–653.
- 335 [15] McCluskey CC. Global Stability for an SEI Epidemiological Model with Continuous Age-
336 Structure in the Exposed and Infectious Classes. *Mathematical biosciences and engineering:*
337 *MBE*. 2012 Oct;9(4):819–841.
- 338 [16] Magal P, Webb G. Predicting the Number of Reported and Unreported Cases for the
339 COVID-19 Epidemic in South Korea, Italy, France and Germany. *medRxiv*. 2020 Mar;p.
340 2020.03.21.20040154.
- 341 [17] Inaba H. Threshold and Stability Results for an Age-Structured Epidemic Model. *Journal of*
342 *Mathematical Biology*. 1990 Jun;28(4):411–434.
- 343 [18] Dietz K, Schenzle D. Proportionate Mixing Models for Age-Dependent Infection Transmission.
344 *Journal of Mathematical Biology*. 1985;22(1):117–120.
- 345 [19] Arguedas YN, Santana-Cibrian M, Velasco-Hernández JX. Transmission Dynamics of Acute
346 Respiratory Diseases in a Population Structured by Age. *Mathematical biosciences and engi-*
347 *neering: MBE*. 2019 Aug;16(6):7477–7493.
- 348 [20] Libin P, Moonens A, Verstraeten T, Perez-Sanjines F, Hens N, Lemey P, et al. Deep Reinforce-
349 ment Learning for Large-Scale Epidemic Control. *arXiv:200313676 [cs]*. 2020 Mar;.
- 350 [21] Singh R, Adhikari R. Age-Structured Impact of Social Distancing on the COVID-19 Epidemic
351 in India. *arXiv:200312055 [cond-mat, q-bio]*. 2020 Mar;.
- 352 [22] Eames KTD, Tilston NL, Brooks-Pollock E, Edmunds WJ. Measured Dynamic Social Contact
353 Patterns Explain the Spread of H1N1v Influenza. *PLoS Computational Biology*. 2012 Mar;8(3).
- 354 [23] Shim E. Optimal Strategies of Social Distancing and Vaccination against Seasonal Influenza.
355 *Mathematical biosciences and engineering: MBE*. 2013 Oct-Dec;10(5-6):1615–1634.
- 356 [24] Hoppensteadt F. An Age Dependent Epidemic Model**This Research Was Supported by the
357 National Science Foundation under Grant No. 32996X2. *Journal of the Franklin Institute*. 1974
358 May;297(5):325–333.
- 359 [25] Djidjou Demasse R, Tewa JJ, Bowong S, Emvudu Y. Optimal Control for an Age-
360 Structured Model for the Transmission of Hepatitis B. *Journal of Mathematical Biology*. 2016
361 Aug;73(2):305–333.
- 362 [26] Anita S. *Analysis and Control of Age-Dependent Population Dynamics. Mathematical Mod-*
363 *elling: Theory and Applications*. Springer Netherlands; 2000.
- 364 [27] Barbu V, Iannelli M. Optimal Control of Population Dynamics. *Journal of Optimization Theory*
365 *and Applications*. 1999 Jul;102(1):1–14.

- 366 [28] Fister KR, Lenhart S. Optimal Control of a Competitive System with Age-Structure. *Journal of*
367 *Mathematical Analysis and Applications*. 2004 Mar;291(2):526–537.
- 368 [29] Ba M, Djidjou-Demasse R, Lam M, Tewa JJ. Optimal Intervention Strategies of Staged Pro-
369 gression HIV Infections through an Age-Structured Model with Probabilities of ART Drop Out.
370 arXiv:191106703 [math, q-bio]. 2019 Nov,;
- 371 [30] Lin F, Muthuraman K, Lawley M. An Optimal Control Theory Approach to Non-Pharmaceutical
372 Interventions. *BMC Infectious Diseases*. 2010 Feb;10(1):32.
- 373 [31] Djidjou-Demasse R, Michalakis Y, Choisy M, Sofonea MT, Alizon S. Optimal COVID-19 Epi-
374 demic Control until Vaccine Deployment. medRxiv. 2020 Apr;p. 2020.04.02.20049189.
- 375 [32] Kantner M, Koprucki T. Beyond Just "Flattening the Curve": Optimal Control of Epidemics
376 with Purely Non-Pharmaceutical Interventions. arXiv:200409471 [physics, q-bio]. 2020 Apr,;
- 377 [33] Perkins A, Espana G. Optimal Control of the COVID-19 Pandemic with Non-Pharmaceutical
378 Interventions. medRxiv. 2020 Apr;p. 2020.04.22.20076018.
- 379 [34] Béraud G, Kazmerczak S, Beutels P, Levy-Bruhl D, Lenne X, Mielcarek N, et al. The French
380 Connection: The First Large Population-Based Contact Survey in France Relevant for the Spread
381 of Infectious Diseases. *PLOS ONE*. 15 juil 2015;10(7):e0133203.
- 382 [35] Thieme HR. Semiflows Generated by Lipschitz Perturbations of Non-Densely Defined Opera-
383 tors. *Differential and Integral Equations*. 1990;3(6):1035–1066.
- 384 [36] Iannelli M. *Mathematical Theory of Age-Structured Population Dynamics*. Giardini editori e
385 stampatori; 1995.
- 386 [37] Demasse RD, Ducrot A. An Age-Structured Within-Host Model for Multistrain Malaria Infec-
387 tions. *SIAM Journal on Applied Mathematics*. 2013 Jan;73(1):572–593.
- 388 [38] Magal P, Ruan S. *Theory and Applications of Abstract Semilinear Cauchy Problems*. Applied
389 *Mathematical Sciences*. Springer International Publishing; 2018.
- 390 [39] Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Impact of Non-
391 Pharmaceutical Interventions (NPIs) to Reduce COVID- 19 Mortality and Healthcare Demand.
392 2020;p. 20.
- 393 [40] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan,
394 China, of Novel Coronavirus–Infected Pneumonia. *New England Journal of Medicine*. 2020
395 Jan,;

- 396 [41] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical Course and Risk Factors for Mortality of
397 Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. *The Lancet*.
398 2020 Mar;.
- 399 [42] Estimation de La Population Au 1^{er} Janvier 2020 | Insee;.
400 <https://www.insee.fr/fr/statistiques/1893198>.
- 401 [43] Pyramide Des Âges | Insee;. <https://www.insee.fr/fr/statistiques/2381472>.
- 402 [44] Données hospitalières relatives à l'épidémie de COVID-19 - data.gouv.fr;. /es/datasets/donnees-
403 hospitalieres-relatives-a-lepidemie-de-covid-19/.
- 404 [45] CDCMMWR. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19)
405 — United States, February 12–March 16, 2020. *MMWR Morbidity and Mortality Weekly Re-*
406 *port*. 2020;69.
- 407 [46] Feichtinger G, Tragler G, Veliov VM. Optimality Conditions for Age-Structured Control Sys-
408 tems. *Journal of Mathematical Analysis and Applications*. 2003 Dec;288(1):47–68.
- 409 [47] Lenhart S, Workman JT. *Optimal Control Applied to Biological Models*. CRC press; 2007.
- 410 [48] Ekeland I. On the Variational Principle. *Journal of Mathematical Analysis and Applications*.
411 1974 Aug;47(2):324–353.
- 412 [49] Salje H, Kiem CT, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al.. Estimating the Burden
413 of SARS-CoV-2 in France; 2020.
- 414 [50] Sofonea MT, Reyné B, Elie B, Djidjou-Demasse R, Selinger C, Michalakis Y, et al. Epidemiolog-
415 ical Monitoring and Control Perspectives: Application of a Parsimonious Modelling Framework
416 to the COVID-19 Dynamics in France. *medRxiv*. 2020 May;p. 2020.05.22.20110593.
- 417 [51] Sakurai A, Sasaki T, Kato S, Hayashi M, Tsuzuki Si, Ishihara T, et al. Natural History of Asymp-
418 tomatic SARS-CoV-2 Infection. *New England Journal of Medicine*. 2020 Jun;0(0):null.
- 419 [52] Buitrago-Garcia DC, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. The
420 Role of Asymptomatic SARS-CoV-2 Infections: Rapid Living Systematic Review and Meta-
421 Analysis. *medRxiv*. 2020 May;p. 2020.04.25.20079103.
- 422 [53] Cohen R, Jung C, Ouldali N, Sellam A, Batard C, Cahn-Sellem F, et al. Assessment of Spread of
423 SARS-CoV-2 by RT-PCR and Concomitant Serology in Children in a Region Heavily Affected
424 by COVID-19 Pandemic. *medRxiv*. 2020 Jun;p. 2020.06.12.20129221.
- 425 [54] Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering How Biological Sex
426 Impacts Immune Responses and COVID-19 Outcomes. *Nature Reviews Immunology*. 2020
427 Jun;p. 1–6.

- 428 [55] Prem K, Cook AR, Jit M. Projecting Social Contact Matrices in 152 Countries Using Contact
429 Surveys and Demographic Data. PLOS Computational Biology. 2017 Sep;13(9):e1005697.
- 430 [56] May RM, Anderson RM. Spatial Heterogeneity and the Design of Immunization Programs.
431 Mathematical Biosciences. 1984 Nov;72(1):83–111.
- 432 [57] Fraser C, Riley S, Anderson RM, Ferguson NM. Factors That Make an Infectious Disease Out-
433 break Controllable. Proceedings of the National Academy of Sciences. 2004 Apr;101(16):6146–
434 6151.




Figure S1: **Practicability of the age-structured optimal control.** (a)-(b) Step optimal controls with a 3-weeks update over the older and younger populations. The corresponding optimal is given by Figure 4b. (c)-(d) Cumulative deaths per age at final time $T = 365$ days.




Figure S2: The effect of paucisymptomatic infections, through their proportion p , on the optimal control c^* .

435 **A The basic reproduction number**

Here we compute the basic reproduction number R_0 of the model (3)-(5). First let us set for $i \geq 0$ and $a \in [0, a_{\max}]$ the following functions

$$\begin{aligned}\pi_s(a, i) &= \exp\left(-i\mu_{nat}(a) - \int_0^i [\gamma_{dir}(a)\mathbf{1}_{[i_{symp}, i_{\max}]}(\sigma) + h_s(a, \sigma)]d\sigma\right), \\ \pi_m(a, i) &= \exp\left(-i\mu_{nat}(a) - \int_0^i h_m(a, \sigma)d\sigma\right), \\ \pi_p(a, i) &= \exp\left(-i\mu_{nat}(a) - \int_0^i h_p(a, \sigma)d\sigma\right),\end{aligned}$$

436 that describe the survival probability of infected individuals (in the respective compartment), with age
437 a , from their infection until the time since infection i , in case of no hospitalisation (*i.e.* $H \equiv 0$). We
438 get the following Volterra formulation of the linearized system of (3)-(5):

$$I_s(t, a, i) = \begin{cases} I_{s,0}(a, i-t) \frac{\pi_s(a, i)}{\pi_s(a, i-t)}, & \text{for } t \in [0, i), \\ (1-p)q(a)\lambda_0(t-i, a)S_0(a)\pi_s(a, i), & \text{for } t \geq i, \end{cases} \quad (\text{A.1})$$

439

$$I_m(t, a, i) = \begin{cases} I_{m,0}(a, i-t) \frac{\pi_m(a, i)}{\pi_m(a, i-t)}, & \text{for } t \in [0, i), \\ (1-p)(1-q(a))\lambda_0(t-i, a)S_0(a)\pi_m(a, i), & \text{for } t \geq i \end{cases} \quad (\text{A.2})$$

440 and

$$I_p(t, a, i) = \begin{cases} I_{A,0}(a, i-t) \frac{\pi_p(a, i)}{\pi_p(a, i-t)}, & \text{for } t \in [0, i), \\ p\lambda_0(t-i, a)S_0(a)\pi_p(a, i), & \text{for } t \geq i \end{cases} \quad (\text{A.3})$$

441 where $\lambda_0 = \lambda(\cdot, \cdot, 0)$ is defined by

$$\lambda_0(t, a) = \int_0^{a_{\max}} K(a, a') \int_0^\infty (\beta_s(a', i)I_s(t, a', i) + \beta_m(a', i)I_m(t, a', i) + \beta_p(a', i)I_p(t, a', i)) di da', \quad (\text{A.4})$$

where $\beta_k, k \in \{s, m, p\}$ are defined in Section 3.2. Let $I_N(t, a) = \lambda_0(t, a)S_0(a)$ be the density of newly infected of age a at time t , with $c \equiv 0$. Then (A.1)-(A.2)-(A.3) can be rewritten as the following Volterra formulation:

$$I_N(t, a) = S_0(a) \int_0^t \int_0^{a_{\max}} K(a, a') \omega(a', i) I_N(t-i, a') da' di + f(t, a),$$

where

$$\omega(a', i) = \beta_s(a', i)(1-p)q(a')\pi_s(a', i) + \beta_m(a', i)(1-p)(1-q(a'))\pi_m(a', i) + \beta_p(a', i)p\pi_p(a', i)$$

and $f(t, a)$ is the density of new infections produced by the initial population. Therefore, the basic reproduction number R_0 is the spectral radius, denoted by $r(U)$, of the next generation operator U defined on $L^1_+(0, a_{\max})$ by

$$U : L^1(0, a_{\max}) \ni v \longmapsto S_0(\cdot) \int_0^\infty \int_0^{a_{\max}} K(\cdot, a') \omega(a', i) v(a') da' di \in L^1(0, a_{\max})$$

442 As explained in Section 3.2, it is estimated in [11] that each average infectiousness β_k ($k \in \{s, m, p\}$)
 443 takes the form of a Weibull distribution $W(3, 5.65)$ so that the mean and median are equal to 5.0
 444 days while the standard deviation is 1.9 days. Based on this estimation, we assume that $\beta_k(a, i) =$
 445 $\alpha \bar{\beta}(i) \xi_k(i)$ where $\bar{\beta} \sim W(3, 5.65)$ and α is a positive parameter to be determined. Consequently, it
 446 follows that α is given by

$$\alpha = \frac{R_0}{r(\bar{U})}, \quad (\text{A.5})$$

where \bar{U} is the operator defined by

$$\bar{U} : L^1(0, a_{\max}) \ni v \mapsto S_0(\cdot) \int_0^\infty \int_0^{a_{\max}} K(\cdot, a') \bar{\omega}(a', i) v(a') da' di \in L^1(0, a_{\max})$$

with

$$\bar{\omega}(a', i) = \bar{\beta}(i) [\xi_s(i)(1-p)q(a')\pi_s(a', i) + \xi_m(i)(1-p)(1-q(a'))\pi_m(a', i) + \xi_p(i)p\pi_p(a', i)].$$

We see that \bar{U} can be rewritten as

$$\bar{U}v(a) = S_0(a) \int_0^{a_{\max}} K(a, a') \bar{\Omega}(a') v(a') da', \quad \forall v \in L^1_+(0, a_{\max}) \quad \text{where} \quad \bar{\Omega}(a') = \int_0^\infty \bar{\omega}(a', i) di.$$

447 Now, in order to compute the spectral radius $r(\bar{U})$, we first make the following assumptions:

448 **Assumption A.1** We suppose that:

449 a) functions $S_0, K, \bar{\Omega}$ are bounded and positive almost everywhere;

450 b) the function K is symmetric.

We can note that the Assumption A.1 is satisfied when using the parameters stated in Table 1. Now, let S be the positive self-adjoint operator defined by

$$S : L^2(0, a_{\max}) \ni v \mapsto \sqrt{S_0(\cdot)\bar{\Omega}(\cdot)} \int_0^{a_{\max}} K(\cdot, a') \sqrt{S_0(a')\bar{\Omega}(a')} v(a') da' \in L^2_+(0, a_{\max})$$

451 (by symmetry of K supposed in Assumption A.1). We can deduce the following

Proposition A.2 The operators \bar{U} and S are positive and compact, their spectra $\sigma(\bar{U}) \setminus \{0\}$ and $\sigma(S) \setminus \{0\}$ are composed of isolated eigenvalues with finite algebraic multiplicity. Moreover, we have $\sigma(\bar{U}) = \sigma(S) \subset \mathbb{R}_+$ and the following Rayleigh formula holds:

$$r(\bar{U}) = r(S) = \sup_{\substack{v \in L^2(0, a_{\max}) \\ \|v\|_{L^2(0, a_{\max})} = 1}} \int_0^{a_{\max}} \int_0^{a_{\max}} K(a, a') \sqrt{S_0(a')\bar{\Omega}(a')} \sqrt{S_0(a)\bar{\Omega}(a)} v(a') v(a) da' da.$$

Proof. The compactness of both integral operators follows from the fact that $a_{\max} < \infty$ by assumption (see Table 1), hence their spectra are punctual. Now we prove that $\sigma(\bar{U}) = \sigma(S)$. Let $v \in \sigma(\bar{U})$ be an eigenvalue of \bar{U} and $\phi \in L^1(0, a_{\max})$ be the associated eigenvector, i.e.

$$\bar{U}\phi(a) = S_0(a) \int_0^{a_{\max}} K(a, a') \bar{\Omega}(a') \phi(a') da' = v\phi(a), \quad \forall a \in [0, a_{\max}]$$

so that $\phi \in L^\infty(0, a_{\max}) \subset L^2(0, a_{\max})$. Defining the function

$$\psi = \frac{\phi \sqrt{\bar{\Omega}}}{\sqrt{S_0}} \in L^2(0, a_{\max})$$

leads to

$$v\psi(a) = \sqrt{S_0(a)\bar{\Omega}(a)} \int_0^{a_{\max}} K(a, a') \sqrt{\bar{\Omega}(a')S_0(a')} \psi(a') da' = S\psi(a), \quad \forall a \in [0, a_{\max}]$$

i.e. $v \in \sigma(S)$ is an eigenvalue of S associated to the eigenvector ψ , so that $\sigma(\bar{U}) \subset \sigma(S)$. For the reverse inclusion, let $v \in \sigma(S)$ and $\psi \in L^2(0, a_{\max}) \subset L^1(0, a_{\max})$ be the associated eigenvector for S . It follows that the function

$$\phi = \frac{\psi \sqrt{S_0}}{\sqrt{\bar{\Omega}}} \in L^1(0, a_{\max})$$

452 is an eigenvector of \bar{U} related to the eigenvalue $v \in \sigma(\bar{U})$, whence $\sigma(\bar{U}) = \sigma(S)$. In particular,
 453 both spectral radius are equal. Finally, the Rayleigh formula is classical for positive and symmetric
 454 operators. ■

Remark A.3 Numerically, to compute $r(\bar{U})$, we can similarly show that it is given by the spectral radius of the following operator:

$$L^1(0, a_{\max}) \ni v \mapsto \int_0^{a_{\max}} K(\cdot, a') \bar{\Omega}(a') S_0(a') v(a') da' \in L^1(0, a_{\max})$$

455 which can be easily computed since the age a is numerically divided into 20 classes, so that the term
 456 inside the integral of the latter equation is a 20×20 matrix. Finally, we obtain α from (A.5).

457 B Computations of the adjoint system

In order to deal with the necessary optimality conditions, we use some results in [46]. Next, we detail the computations of the adjoint system (12)-(13). To this end, we first define the functions $y_1, Q: [0, T] \times [0, a_{\max}] \rightarrow \mathbb{R}$ and $y_2: [0, T] \times [0, a_{\max}] \times \mathbb{R}_+$ by:

$$y_1(t, a) = \begin{pmatrix} S(t, a) \\ R(t, a) \end{pmatrix} \quad y_2(t, a, i) = \begin{pmatrix} I_s(t, a, i) \\ I_m(t, a, i) \\ I_p(t, a, i) \end{pmatrix}, \quad Q(t, a) = \begin{pmatrix} H(t) & E(t, a) & b(t, a) \end{pmatrix}$$

458 wherein

$$g_H(i, y_2(t, a, i)) = I_s(t, a, i) 1_{[i_{\text{symp}}, \infty)}(i), \quad g_R(i, y_2(t, a, i)) = \sum_{k \in \{s, m, p\}} h_k(a, i) I_k(t, a, i),$$

$$g_\lambda(a, i, y_1, y_2) = S(t, a) \int_0^{a_{\max}} K(a, a') (\beta_s(a', i) I_s(t, a', i) + \beta_m(a', i) I_m(t, a', i) + \beta_p(a', i) I_p(t, a', i)) da',$$

$$H(t) = \int_0^\infty \int_0^{a_{\max}} g_H(i, y_2(t, a, i)) da di, \quad E(t, a) = \int_0^\infty g_\lambda(a, i, y_1(t, a, i), y_2(t, a, i)) di,$$

$$b(t, a) = \int_0^\infty g_R(i, y_2(t, a, i)) di.$$

The model (5) thus rewrites as

$$\begin{cases} \partial_t y_1(t, a) &= F_1(a, Q(t, a), c(t, a), y_1(t, a)), \\ (\partial_t + \partial_i) y_2(t, a, i) &= F_2(a, i, Q(t, a), c(t, a), y_2(t, a, i)), \\ y_2(t, a, 0) &= \Phi(a, c(t, a), E(t, a)), \end{cases}$$

with

$$F_1(a, Q(t, a), c(t, a), y_1(t, a)) = \begin{pmatrix} -\mu(a, H(t))S(t, a) - (1 - c(t, a))E(t, a) \\ -\mu(a, H(t))R(t, a) + b(t, a) \end{pmatrix},$$

$$F_2(a, i, Q(t, a), c(t, a), y_2(t, a, i)) = \begin{pmatrix} -(\mu(a, H(t)) + \gamma(a, i, H(t)) + h_s(a, i))I_s(t, a, i) \\ -(\mu(a, H(t)) + h_m(a, i))I_m(t, a, i) \\ -(\mu(a, H(t)) + h_p(a, i))I_p(t, a, i) \end{pmatrix}$$

and

$$\Phi(a, c(t, a), Q(t, a)) = \begin{pmatrix} (1 - p)q(a)(1 - c(t, a))E(t, a) \\ (1 - p)(1 - q(a))(1 - c(t, a))E(t, a) \\ p(1 - c(t, a))E(t, a) \end{pmatrix}.$$

We now rewrite the functional J as

$$J(c) = \int_0^T \int_0^{a_{\max}} \left(\mathcal{J}_1(a, c(t, a), Q(t, a), y_1(t, a)) + \int_0^\infty \mathcal{J}_2(a, i, Q(t, a), y_2(t, a, i)) di \right) da dt$$

which is decomposed into

$$\mathcal{J}_1(a, c(t, a), Q(t, a), y_1(t, a)) = \mu_{add}(a, H(t))(S(t, a) + R(t, a)) + B(a)c^2(t, a)$$

and

$$\mathcal{J}_2(a, i, Q(t, a), y_2(t, a, i)) = \gamma(a, i, H(t))I_s(t, a, i) + \mu_{add}(a, H(t))(I_s(t, a, i) + I_m(t, a, i) + I_p(t, a, i)).$$

We denote by $z_1, \zeta_k : [0, T] \times [0, a_{\max}] \rightarrow \mathbb{R}$ (for $k \in \{1, 2, 3\}$) the following adjoint functions

$$z_1(t, a) = (z_S(t, a), z_R(t, a)), \quad \zeta(t, a) = (\zeta_1(t, a), \zeta_2(t, a), \zeta_3(t, a)),$$

and we denote by $z_2 : [0, T] \times [0, a_{\max}] \times \mathbb{R}_+$ the following adjoint function

$$z_2(t, a, i) = (z_{I_s}(t, a, i), z_{I_m}(t, a, i), z_{I_p}(t, a, i)),$$

satisfying $\lim_{i \rightarrow \infty} z_2(t, a, i) = 0$ and $z_1(T, a) = z_2(T, a, i) = 0$. We get

$$\nabla_{y_1} \mathcal{J}_1(a, c(t, a), Q(t, a), y_1(t, a)) = \begin{pmatrix} \mu_{add}(a, H(t)) \\ \mu_{add}(a, H(t)) \end{pmatrix}^T$$

$$\nabla_{y_2} \mathcal{J}_2(a, i, Q(t, a), y_2(t, a, i)) = \begin{pmatrix} \mu_{add}(a, H(t)) + \gamma(a, i, H(t)) \\ \mu_{add}(a, H(t)) \\ \mu_{add}(a, H(t)) \end{pmatrix}^T$$

$$\nabla_{y_1} F_1(a, Q(t, a), c(t, a), y_1(t, a)) = \begin{pmatrix} -\mu(a, H(t)) & 0 \\ 0 & -\mu(a, H(t)) \end{pmatrix}$$

and

$$\nabla_{y_2} F_2 = \begin{pmatrix} -\mu(a, H(t)) - \gamma(a, i, H(t)) - h_s(a, i) & 0 & 0 \\ 0 & -\mu(a, H(t)) - h_m(a, i) & 0 \\ 0 & 0 & -\mu(a, H(t)) - h_p(a, i) \end{pmatrix}.$$

Then

$$(z_1 \cdot \nabla_{y_1} F_1)(t, a) = \begin{pmatrix} -\mu(a, H(t)) z_S(t, a) & -\mu(a, H(t)) z_R(t, a) \end{pmatrix}$$

and

$$(z_2 \cdot \nabla_{y_2} F_2)(t, a, i) = \begin{pmatrix} -(\mu + \gamma + h_s) z_{I_s}(t, a, i) & -(\mu + h_m) z_{I_m}(t, a, i) & -(\mu + h_p) z_{I_p}(t, a, i) \end{pmatrix}.$$

Setting

$$g_1(a, y_1, y_2) = \begin{pmatrix} \int_0^\infty g_H(i, y_2(t, a, i)) di \\ E(t, a) \\ b(t, a) \end{pmatrix}, \quad g_2(a, i, y_1, y_2) = \begin{pmatrix} g_H(i, y_2(t, a, i)) \\ g_\lambda(a, i, y_1(t, a, i), y_2(t, a, i)) \\ g_R(i, y_2(t, a, i)) \end{pmatrix},$$

we see that

$$\nabla_{y_1} g_1(a, y_1, y_2) = \begin{pmatrix} 0 & 0 \\ \int_0^\infty \int_0^{a_{\max}} K(a, a') (\beta_s(a', i) I_s(t, a', i) + \beta_m(a', i) I_m(t, a', i) + \beta_p(a', i) I_p(t, a', i)) da' di & 0 \\ 0 & 0 \end{pmatrix}$$

and

$$\nabla_{y_2} g_2(a, i, y_1, y_2) = \begin{pmatrix} \mathbf{1}_{[i_{\text{symp}}, \infty)}(i) & 0 & 0 \\ S(t, \cdot) \beta_s(a, i) K(\cdot, a) & S(t, \cdot) \beta_m(a, i) K(\cdot, a) & S(t, \cdot) \beta_p(a, i) K(\cdot, a) \\ h_s(a, i) & h_m(a, i) & h_p(a, i) \end{pmatrix}.$$

From there, we deduce that

$$(\zeta \cdot \nabla_{y_1} g_1)(t, a) = \left(\zeta_2(t, a) \int_0^\infty \int_0^{a_{\max}} K(a, a') (\beta_s(a', i) I_s(t, a', i) + \beta_m(a', i) I_m(t, a', i) + \beta_p(a', i) I_p(t, a', i)) da' di \quad 0 \right)$$

and

$$(\zeta \cdot \nabla_{y_2} g_2)(t, a, i) = \begin{pmatrix} \zeta_1(t, a) \mathbf{1}_{[i_{\text{symp}}, \infty)}(i) + \beta_s(a, i) \int_0^{a_{\max}} \zeta_2(t, a') S(t, a') K(a', a) da' + \zeta_3(t, a) h_s(a, i) \\ \beta_m(a, i) \int_0^{a_{\max}} \zeta_2(t, a') S(t, a') K(a', a) da' + \zeta_3(t, a) h_m(a, i) \\ \beta_p(a, i) \int_0^{a_{\max}} \zeta_2(t, a') S(t, a') K(a', a) da' + \zeta_3(t, a) h_p(a, i) \end{pmatrix}^T.$$

The adjoint system is given by

$$\begin{cases} -\frac{\partial z_1}{\partial t}(t, a) & = \nabla_{y_1} \mathcal{J}_1(t, a) + (z_1 \cdot \nabla_{y_1} F_1)(t, a) + (\zeta \cdot \nabla_{y_1} g_1)(t, a) \\ -\left(\frac{\partial z_2}{\partial t} + \frac{\partial z_2}{\partial i}\right)(t, a, i) & = \nabla_{y_2} \mathcal{J}_2(t, a) + (z_2 \cdot \nabla_{y_2} F_2)(t, a, i) + (\zeta \cdot \nabla_{y_2} g_2)(t, a, i) \end{cases}$$

which is equivalent to (12). Next, we see that

$$\nabla_Q \Phi(t, a) = \begin{pmatrix} 0 & (1-p)q(a)(1-c(t, a)) & 0 \\ 0 & (1-p)(1-q(a))(1-c(t, a)) & 0 \\ 0 & p(1-c(t, a)) & 0 \end{pmatrix}$$

whence

$$(z_2(\cdot, \cdot, 0) \cdot \nabla_Q \Phi)(t, a) = \left(0 \quad [1-c(t, a)][(1-p)(q(a)z_{I_s} + (1-q(a))z_{I_m}) + pz_{I_p}](t, a, 0) \quad 0 \right).$$

Further, we have

$$\nabla_Q \mathcal{J}_1(t, a) = \left(\frac{\partial \mu}{\partial H}(a, H(t))(S(t, a) + R(t, a)) \quad 0 \quad 0 \right)$$

and

$$\nabla_Q \mathcal{J}_2(t, a, i) = \left(\frac{\partial \mu}{\partial H}(a, H(t))(I_s(t, a, i) + I_m(t, a, i) + I_p(t, a, i)) + \frac{\partial \gamma}{\partial H}(a, i, H(t))I_s(t, a, i) \quad 0 \quad 0 \right).$$

We also see that $\nabla_Q g_1 \equiv 0$, $\nabla_Q g_2 \equiv 0$,

$$\nabla_Q F_1(t, a) = \begin{pmatrix} -\frac{\partial \mu}{\partial H}(a, H(t))S(t, a) & -(1-c(t, a)) & 0 \\ -\frac{\partial \mu}{\partial H}(a, H(t))R(t, a) & 0 & 1 \end{pmatrix}$$

and

$$\nabla_Q F_2(t, a, i) = \begin{pmatrix} -\left(\frac{\partial \mu}{\partial H}(a, H(t)) + \frac{\partial \gamma}{\partial H}(a, i, H(t))\right)I_s(t, a, i) & 0 & 0 \\ -\frac{\partial \mu}{\partial H}(a, H(t))I_m(t, a, i) & 0 & 0 \\ -\frac{\partial \mu}{\partial H}(a, H(t))I_p(t, a, i) & 0 & 0 \end{pmatrix}$$

whence

$$(z_1 \cdot \nabla_Q F_1)(t, a) = \begin{pmatrix} -\frac{\partial \mu}{\partial H}(a, H(t))S(t, a)z_S(t, a) - \frac{\partial \mu}{\partial H}(a, H(t))R(t, a)z_R(t, a) \\ -(1-c(t, a))z_S(t, a) \\ z_R(t, a) \end{pmatrix}^T$$

and

$$(z_2 \cdot \nabla_Q F_2)(t, a, i) = \left(-\left(\frac{\partial \mu}{\partial H} + \frac{\partial \gamma}{\partial H}\right)I_s z_{I_s} - \frac{\partial \mu}{\partial H}I_m z_{I_m} - \frac{\partial \mu}{\partial H}I_p z_{I_p} \quad 0 \quad 0 \right).$$

Finally, the adjoint functions ζ must satisfy the following equation:

$$\begin{aligned} \zeta(t, a) &= (z_2(\cdot, \cdot, 0) \cdot \nabla_Q \Phi)(t, a) + (\nabla_Q \mathcal{J}_1)(t, a) + (z_1 \cdot \nabla_Q F_1)(t, a) + (\zeta \cdot \nabla_Q g_1)(t, a) \\ &\quad + \int_0^\infty ((\nabla_Q \mathcal{J}_2)(t, a, i) + (z_2 \cdot \nabla_Q F_2)(t, a, i) + (\zeta \cdot \nabla_Q g_2)(t, a, i)) di \end{aligned}$$

which is equivalent to (13). Finally, the Hamiltonian is given by

$$\mathcal{H}(t, a, c) = z_2(t, a, 0) \cdot \Phi(t, a, c, Q) + \mathcal{J}_1(a, c, Q, y_1) + \int_0^\infty \mathcal{J}_2(a, i, Q, y_2) di$$

which leads to

$$\begin{aligned} \mathcal{H}(t, a, c) &= E(t, a)[1-c(t, a)][(1-p)(q(a)z_{I_s} + (1-q(a))z_{I_m}) + pz_{I_p}](t, a, 0) \\ &\quad + \mu_{add}(a, H(t))(S(t, a) + R(t, a)) + B(a)c^2(t, a) \\ &\quad + \int_0^\infty (\gamma(a, i, H(t))I_s(t, a, i) + \mu_{add}(a, H(t))(I_s(t, a, i) + I_m(t, a, i) + I_p(t, a, i))) di. \end{aligned} \quad (\text{B.1})$$